IOLCP Q2 FY26: PAT up 56.7% YoY, EBITDA margin at 11.1%

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+11.7%Reaction day

₹88.63

prior close

₹93.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+10.8% vs market

Pharmaceuticals peers, median of 157sector+0.8%+10.9% vs sector

On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 10.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.5

10m

+5.9

15m

+7.0

30m

+6.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+11.7+0.9+10.8+0.8+10.9

Next day

+10.1+0.8+9.3+0.5+9.7

+7.7+0.7+6.9+0.4+7.3

+7.8+1.3+6.5+0.4+7.4

+5.4+0.5+4.9-0.1+5.5

+4.1+0.4+3.8-0.6+4.7

+1.8-1.5+3.3-1.2+3.0

15d

-1.5-2.4+0.9-1.8+0.3

-6.4-4.4-2.0-2.6-3.8

-14.6-7.2-7.4-5.4-9.3

-15.9-5.0-10.9-5.7-10.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 revenue grew 7.9% YoY to Rs 567.5 Cr. EBITDA up 33.3% at Rs 64 Cr with margin expanding 212 bps to 11.1%. PAT surged 56.7% to Rs 30 Cr. H1 FY26 revenue up 8.9% at Rs 1,119 Cr, EBITDA up 25.7% at Rs 133.5 Cr, PAT up 31% at Rs 64 Cr. Both Pharma and Chemicals segments posted YoY EBIT growth.

Likely market impact

Strong margin expansion and PAT growth signal operational improvement. Pharma traction in non-Ibuprofen APIs and UK entry boost outlook.